Cartesian Therapeutics Grants Option for 50,000 Shares
The stock option, priced at $6.34 per share, was issued to one new employee as an inducement to join the company.
Updated on Nov. 3, 2026 in Biotech
Cartesian Therapeutics has granted an option to purchase 50,000 shares of its common stock to one new employee. The exercise price of $6.34 per share equals the closing trading price on the Nasdaq Global Market on the grant date.
Why it matters
The grant was made as an inducement to the employee's entry into employment and was approved by the company's board of directors under Nasdaq Listing Rule 5635(c)(4). For Maryland readers, it reflects routine equity compensation activity at a Frederick-based biotech company listed on a major U.S. exchange.
The option covers 50,000 shares with an exercise price of $6.34 and a ten-year term, with 25% vesting on November 2, 2027, followed by thirty-six substantially equal monthly installments. The filing does not disclose the employee's position or the company's total outstanding option count.
The players
Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company based in Frederick, Maryland, whose common stock trades on the Nasdaq Global Market.
The details
Cartesian Therapeutics, headquartered in Frederick, Maryland, granted the option on November 2, 2026, under its Amended and Restated 2018 Employment Inducement Incentive Award Plan. The option vests in stages and will be fully vested on November 2, 2030.
Timeline
November 2, 2026: Option granted to the new employee at $6.34 per share.
November 2, 2027: First 25% of the option vests.
November 2, 2030: Option becomes fully vested.
Roadmap
Inducement grants under Nasdaq Listing Rule 5635(c)(4) let listed companies compensate new hires without a shareholder vote, a mechanism used widely across the biotech sector to recruit talent. This Cartesian grant follows that established pattern rather than departing from it.
For employees and prospective hires, equity grants like this one tie compensation to share price over a multi-year vesting schedule. Shareholders and job seekers in the Maryland biotech sector can track such grants in the company's public filings.
The takeaway
Equity inducement grants with multi-year vesting are a common way biotech companies recruit and retain staff. Readers tracking a company's compensation can review its filings for option terms, exercise prices, and vesting schedules.
Further reading
For more on the state's life sciences sector, see Biotech coverage for Maryland readers.
